12 · PublicStrategic Investment Series · Illustrated Overview
4 pages
OBIS STRATEGIC INVESTMENT SERIES · 2027
Investor & Strategic Alliances Center
An institutional gateway to the OBIS platform, its investment framework and opportunities for international scientific and strategic collaboration.
Explore the series ↓
72Proposed products · six generations
2027–2034Development horizon
US$1.2MSeed financing
US$5.448BCentral pre-money valuation · model-derived
The central valuation is derived from the current OBIS model. Read document 06 for the methodology and assumptions.
START HERE
The institutional introduction
12 · PublicStrategic Investment Series · Executive Dossier
4 pages
14 · PublicStrategic Investment Series · Flyer
1 page
TEN FOUNDATIONAL DOCUMENTS
OBIS Strategic Investment Series – 2027
Original sequence, complete documents. Eight public editions; documents 07 and 09 require individual authorization.
Executive Synthesis & Strategic Investment Overview
EN · 10 pages · Public
Executive Financial Overview
EN · 10 pages · Public
LPS™ Commercial & Health-Economic Case
EN · 10 pages · Public
SPI™ Strategic Market Comparison
EN · 10 pages · Public
Platform Portfolio · 72 Products · 2027–2034
EN · 10 pages · Public
Pre-Money Valuation
EN · 12 pages · PublicSeed Financing Structure · US$1.2M
EN · 9 pages · Authorized access
Use of Funds, Milestones & Value Inflection
EN · 9 pages · PublicIP Portfolio & Patent Pending Roadmap
EN · 9 pages · Authorized access
Strategic Collaboration Framework
EN · 9 pages · PublicINSTITUTIONAL RESEARCH & METHODOLOGICAL FOUNDATIONS
The Value of Innovation Potential (VIP)
Foundations and an Integrative Research Perspective in Biotechnology
OBIS Innovation & Solutions, Inc. · Institutional Research Monograph · Revised edition · October 2026 · 23 pages
This revised edition places the value of innovation potential within the valuation literature and acknowledges the historical contributions of its researchers. It distinguishes established foundations, proposed interpretations and hypotheses open to research.
The monograph examines platform capabilities, real options, probabilistic modeling and buyer-specific effects through five selected biopharmaceutical acquisitions, complementary market observations, the longitudinal case of Keytruda (Pembrolizumab, Merck), and a fictional biotechnology case study. Ten academic references and eleven documentary sources support its integrative research perspective.
Developed within OBIS Innovation & Solutions’ human–AI co-creation framework, the publication is intended to encourage methodological dialogue among researchers, universities, technology-transfer professionals, investors, and strategic partners.
Research status: Conceptual research perspective; its incremental analytical usefulness remains open to investigation and independent review.
A SHARED FUTURE
Building together through knowledge
At OBIS, we understand collaboration as a meeting of knowledge, capabilities and purpose. Every contribution—scientific, institutional, strategic or financial—can broaden our understanding and help us turn ideas into projects of shared benefit.
We invite you to begin a dialogue, explore shared questions and build long-term relationships grounded in rigor, trust and mutual respect, valuing each person's contributions.
One Vision. Three Paradigms. A Shared Future.
Begin a dialogue →INSTITUTIONAL RELATIONS
Institutional Agreements & Digital Signature Center
Explore the NDA and MoU pathways, submit an institutional request and learn how private electronic signing works after mutual approval.
Enter the agreements center →CORPORATE INFORMATION & CONTACT
OBIS Innovation & Solutions, Inc.New York Mailing Address99 Wall Street #1546New York, NY 10005United Statescontact@obisinnovation.com
Specific institutional agreements, formulations and protected technical information are outside this public collection.